---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069819"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:33:05.837376+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics Q1 net loss $7.3M; pipeline milestones for COYA 302 detailed

## Summary
- Net loss of $7.3M in Q1 2025 vs $5.1M in Q1 2024; R&D expense rose to $5.2M from $3.1M.
- Cash and cash equivalents $35.5M as of March 31, 2025.
- Positive interim results from investigator-initiated trial of LD IL-2 + CTLA4-Ig in Frontotemporal Dementia.
- Expects IND submission for COYA 302 in ALS in Q2 2025; $8.4M milestone from DRL due upon first dosing.
- Plans to file IND for COYA 302 in FTD by end of 2025.

## SEC filing metadata
- accession: 0000950170-25-069819
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017025069819/0000950170-25-069819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017025069819/coya-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069819
- JSON: https://secwatch.observer/filing/0000950170-25-069819.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.